• 1
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61: 6990.
  • 2
    Harford JB. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol 2011; 12: 30612.
  • 3
    MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S. Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43: 20921.
  • 4
    Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control 2001; 12: 491500.
  • 5
    Yang XR, Chang-Claude J, Goode L, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 25063.
  • 6
    Russo IH, Koszalka M, Russo J. Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br J Cancer 1991; 64: 4814.
  • 7
    Russo J, Russo IH. Role of differentiation in the pathogenesis and prevention of breast cancer. J Endocrinol 1997; 4: 721.
  • 8
    Russo J, Russo IH, eds. Molecular basis of breast cancer: prevention and treatment. Berlin: Springer-Verlag, 2004. 447 p.
  • 9
    Russo J, Balogh GA, Russo IH. Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiol Biomarkers Prev 2008; 17: 5166.
  • 10
    Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res 2010; 3: 30111.
  • 11
    Medina D: Breast cancer: the protective effect of pregnancy. Clin Cancer Res 2004; 10: 380S4S.
  • 12
    D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA, Chodosh L. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 2002; 16: 203451.
  • 13
    Belitskaya-Levy I, Zeleniuch-Jacquotte A, Russo J, Russo IH, Bordas P, Ahman J, Afanasyeva Y, Johansson R, Lenner P, Li X, Lopez de Cicco R, Peri S, Ross E, Russo PA, Santucci-Pereira J, Sheriff FS, Slifker M, Hallmans G, Toniolo P, Arslan AA. Characterization of a genomic signature of pregnancy in the breast. Cancer Prev Res 2011; 4: 124.
  • 14
    Mello ML, Vidal BC, Russo IH, Lareef MH, Russo J. DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis. Mutat Res 2007; 617: 17.
  • 15
    Mello ML, Russo P, Russo J, Vidal BC. Entropy of Feulgen-stained 17-beta-estradiol-transformed human breast epithelial cells as assessed by restriction enzymes and image analysis. Oncol Rep 2009; 21: 14837.
  • 16
    Doudkine A, MaCaulay C, Poulin N, Palcic B. Nuclear texture measurements in image cytometry. Pathologica 1995; 87: 28699.
  • 17
    Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008; 68: 1097104.
  • 18
    Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 18593.
  • 19
    Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 11827.
  • 20
    Smyth G K. limma: Linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R. Huber W, eds. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer, 2005: 397420.
  • 21
    Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
  • 22
    Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009; 417: 1527.
  • 23
    Herrmann A, Fleischer K, Czajkowska H, Müller-Newen G, Becker W. Characterization of cyclin L1 as an immobile component of the splicing factor compartment. FASEB J 2007; 21: 314252.
  • 24
    Russo J, Rivera R, Russo IH. Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 1992; 23: 2118.
  • 25
    Russo IH, Russo J. Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 2011; 16: 22133.
  • 26
    Golob JL, Paige SL, Muskheli V, Pabon L, Murry CE. Chromatin remodeling during mouse and human embryonic stem cell differentiation. Dev Dyn 2008; 237: 138998.
  • 27
    Wilson BJ, Giguère V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008; 4: 7: 49.
  • 28
    Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol 2010; 222: 429.
  • 29
    Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 1996; 104: 93867.
  • 30
    Russo J, Tait L, Russo IH. Susceptibility of the mammary gland to carcinogenesis: III. The cell of origin of rat mammary carcinoma. Am J Path 1983; 113: 5066.
  • 31
    Bussolati G, Marchiò C, Gaetano L, Lupo R, Sapino A. Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. J Cell Mol Med 2008; 12: 20918.
  • 32
    Tan PH, Goh BB, Chiang G, Bay BH. Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 2001; 14: 93741.
  • 33
    Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma. Int J Gynecol Cancer 2008; 18: 692701.
  • 34
    Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 103943.
  • 35
    Kubicek S, Schotta G, Lachner M, Sengupta R, Kohlmaier A, Perez-Burgos L, Linderson Y, Martens JH, O'Sullivan RJ, Fodor BD, Yonezawa M, Peters AH, et al. The role of histone modifications in epigenetic transitions during normal and perturbed development. Ernst Schering Res Found Workshop 2006; 57: 127.
  • 36
    Lin W, Dent SY. Functions of histone-modifying enzymes in development. Curr Opin Genet Dev 2006; 16: 13742.
  • 37
    Matthew GG, Young RA. Repressive transcription. Science 2010; 329: 1501.
  • 38
    Erwin JA, Lee JT. Characterization of X-chromosome inactivation status in human pluripotent stem cells. Curr Protoc Stem Cell Biol 2010;Chapter 1:Unit 1B.6.
  • 39
    Navarro P, Chambers I, Karwacki-Neisius V, Chureau C, Morey C, Rougeulle C, Avner P. Molecular coupling of Xist regulation and pluripotency, Science 2008; 321: 16935.
  • 40
    Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 2007; 128: 74762.
  • 41
    Lee JT. Characterization of X-chromosome inactivation status in human pluripotent stem cells. Curr Protoc Stem Cell Biol 2010;Chapter 1:Unit 1B.6.
  • 42
    Taga Y, Miyoshi M, Okajima T, Matsuda T, Nadano D. Identification of heterogeneous nuclear ribonucleoprotein A/B as a cytoplasmic mRNA-binding protein in early involution of the mouse mammary gland. Cell Biochem Funct 2010; 28: 3218.
  • 43
    Huang PR, Hung SC, Wang TC. Telomeric DNA-binding activities of heterogeneous nuclear ribonucleoprotein A3 in vitro and in vivo. Biochim Biophys Acta 2010; 1803: 116474.
  • 44
    Han SP, Friend LR, Carson JH, Korza G, Barbarese E, Maggipinto M, Hatfield JT, Rothnagel JA, Smith R. Differential subcellular distributions and trafficking functions of hnRNP A2/B1 spliceoforms. Traffic 2010; 11: 88698.
  • 45
    Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, Zhao W, Kocak M, Kidd VJ, Lahti JM. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem 2008; 283: 772132.
  • 46
    Yang L, Li N, Wang C, Yu Y, Yuan L, Zhang M, Cao X. Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem 2004; 279: 1163948.
  • 47
    Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY. Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci USA 2008; 105: 1570813.
  • 48
    Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, et al. p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer 2011; 128: 30418.
  • 49
    Salomonis N, Schlieve CR, Pereira L, Wahlquist C, Colas A, Zambon AC, Vranizan K, Spindler MJ, Pico AR, Cline MS, Clark TA, Williams A, et al. Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci USA 2010; 107: 105149.